Topical Insulin for Glaucoma
Topical Insulin for Glaucoma and Optic Neuropathies
Stanford University
52 participants
Apr 1, 2022
INTERVENTIONAL
Conditions
Summary
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Topical insulin 100 U/ml, 1 drop per day
Topical insulin 500 U/ml, 1 drop per day
1 drop of low dose insulin twice daily.
1 drop of high dose insulin twice daily
1 drop of low dose insulin three times daily.
1 drop of high dose insulin three times daily.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05206877